| A critical role for Syk in signal transduction and phagocytosis mediated by Fcγ receptors on macrophages MT Crowley, PS Costello, CJ Fitzer-Attas, M Turner, F Meng, C Lowell, ... Journal of Experimental Medicine 186 (7), 1027-1039, 1997 | 665 | 1997 |
| Verification, analytical validation, and clinical validation (V3): the foundation of determining fit-for-purpose for Biometric Monitoring Technologies (BioMeTs) JC Goldsack, A Coravos, JP Bakker, B Bent, AV Dowling, C Fitzer-Attas, ... npj digital Medicine 3 (1), 55, 2020 | 397 | 2020 |
| Fcγ receptor–mediated phagocytosis in macrophages lacking the Src family tyrosine kinases Hck, Fgr, and Lyn CJ Fitzer-Attas, M Lowry, MT Crowley, AJ Finn, F Meng, AL DeFranco, ... Journal of Experimental Medicine 191 (4), 669-682, 2000 | 332 | 2000 |
| A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in … O Rascol, CJ Fitzer-Attas, R Hauser, J Jankovic, A Lang, JW Langston, ... The Lancet Neurology 10 (5), 415-423, 2011 | 280 | 2011 |
| An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-β derivatives EM Sigurdsson, E Knudsen, A Asuni, C Fitzer-Attas, D Sage, ... Journal of Neuroscience 24 (28), 6277-6282, 2004 | 194 | 2004 |
| Data Analytics from Enroll‐HD, a Global Clinical Research Platform for Huntington's Disease GB Landwehrmeyer, CJ Fitzer‐Attas, JD Giuliano, N Gonçalves, ... Movement Disorders Clinical Practice 4 (2), 212-224, 2017 | 187 | 2017 |
| Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease RA Hauser, MF Lew, HI Hurtig, WG Ondo, J Wojcieszek, CJ Fitzer‐Attas, ... Movement Disorders 24 (4), 564-573, 2009 | 185 | 2009 |
| Altered levels of protein kinase C and Ca2+-dependent protein kinases in human colon carcinomas JG Guillem, CA O'Brian, CJ Fitzer, KA Forde, P LoGerfo, M Treat, ... Cancer research 47 (8), 2036-2039, 1987 | 178 | 1987 |
| Increased melanoma risk in Parkinson disease: a prospective clinicopathological study JM Bertoni, JP Arlette, HH Fernandez, C Fitzer-Attas, K Frei, MN Hassan, ... Archives of neurology 67 (3), 347-352, 2010 | 140 | 2010 |
| Increased melanoma risk in Parkinson disease: a prospective clinicopathological study JM Bertoni, JP Arlette, HH Fernandez, C Fitzer-Attas, K Frei, MN Hassan, ... Archives of neurology 67 (3), 347-352, 2010 | 140 | 2010 |
| The regulation of protein kinase C by chenodeoxycholate, deoxycholate and several structurally related bile acids CJ Fitzer, CA O'Brian, JG Guillem, IB Weinstein Carcinogenesis 8 (2), 217-220, 1987 | 134 | 1987 |
| Mechanisms compensating for dopamine loss in early Parkinson disease J Brotchie, C Fitzer-Attas Neurology 72 (7 Supplement 2), S32-S38, 2009 | 130 | 2009 |
| HD‐CAB: A cognitive assessment battery for clinical trials in Huntington's disease1,2,3 JC Stout, S Queller, KN Baker, S Cowlishaw, C Sampaio, C Fitzer‐Attas, ... Movement Disorders 29 (10), 1281-1288, 2014 | 118 | 2014 |
| The T-body approach: potential for cancer immunotherapy Z Eshhar, N Bach, CJ Fitzer-Attas, G Grosse, J Lustgarten, T Waks, ... Springer seminars in immunopathology 18, 199-209, 1996 | 112 | 1996 |
| Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial W Poewe, K Seppi, CJ Fitzer-Attas, GK Wenning, S Gilman, PA Low, ... The Lancet Neurology 14 (2), 145-152, 2015 | 100 | 2015 |
| Harnessing Syk family tyrosine kinases as signaling domains for chimeric single chain of the variable domain receptors: optimal design for T cell activation CJ Fitzer-Attas, DG Schindler, T Waks, Z Eshhar The Journal of Immunology 160 (1), 145-154, 1998 | 91 | 1998 |
| Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson’s disease: a pharmacogenetic study M Masellis, S Collinson, N Freeman, M Tampakeras, J Levy, A Tchelet, ... Brain 139 (7), 2050-2062, 2016 | 71 | 2016 |
| Studies on protein kinase C and colon carcinogenesis JG Guillem, CA O'Brian, CJ Fitzer, MD Johnson, KA Forde, P LoGerfo, ... Archives of Surgery 122 (12), 1475-1478, 1987 | 58 | 1987 |
| Long‐term effects of rasagiline and the natural history of treated Parkinson's disease O Rascol, RA Hauser, F Stocchi, CJ Fitzer‐Attas, Y Sidi, V Abler, ... Movement Disorders 31 (10), 1489-1496, 2016 | 55 | 2016 |
| Fit‐for‐Purpose Biometric Monitoring Technologies: Leveraging the Laboratory Biomarker Experience A Godfrey, B Vandendriessche, JP Bakker, C Fitzer‐Attas, N Gujar, ... Clinical and translational science 14 (1), 62-74, 2021 | 52 | 2021 |
Robert HauserProfessor of Neurology, University of South Floridaایمیل تأیید شده در health.usf.edu